Pomalidomide-PEG3-OH

Background Introduction

Pomalidomide-PEG3-OH is a synthetic E3 ligase ligand-linker conjugate widely utilized in the development of Proteolysis Targeting Chimeras (PROTACs). This compound features pomalidomide, a well-characterized cereblon (CRBN) E3 ligase ligand, covalently linked to a triethylene glycol (PEG3) spacer with a terminal hydroxyl group. The PEG3 linker provides optimal flexibility and solubility, making this conjugate a versatile building block for assembling innovative chemical probes and targeted protein degraders.

Mechanism

Pomalidomide-PEG3-OH operates as a bifunctional molecule in PROTAC technologies. The pomalidomide moiety binds selectively to the CRBN E3 ubiquitin ligase, a key component of the ubiquitin-proteasome system. The PEG3 linker, ending with a reactive hydroxyl group, enables straightforward conjugation to target protein ligands via esterification or other chemoselective coupling strategies. When incorporated into a PROTAC molecule, this conjugate facilitates the proximity-induced ubiquitination of the target protein, ultimately directing its proteasomal degradation and resulting in potent, selective, and catalytic removal of disease-related proteins.

Applications

Pomalidomide-PEG3-OH is widely used in the research and development of PROTACs for targeted protein degradation. Its primary applications include: (1) serving as a chemical handle in the synthesis of bifunctional molecules targeting a diverse range of disease-relevant proteins for therapeutic intervention in oncology, immunology, and neurodegenerative disorders; (2) enabling structure-activity relationship (SAR) studies to optimize linker length and flexibility in novel PROTAC designs; and (3) facilitating the creation of new chemical probes for the validation and investigation of protein function through selective degradation pathways. This makes Pomalidomide-PEG3-OH an essential component for academics and pharmaceutical companies pushing the frontiers of targeted protein degradation technologies.

The Pomalidomide-PEG3-OH is an E3 Ligase Ligand-Linker Conjugate that plays a crucial role in the development of PROTACs by facilitating the targeted degradation of proteins. This molecule combines a pomalidomide-based ligand with a polyethylene glycol (PEG) linker, offering enhanced solubility and flexibility for efficient target engagement. The following provides a detailed description of this molecule.

Linker: The linker in this molecule is a triethylene glycol (PEG3) unit, known for its optimal balance of flexibility and length, which enhances the solubility and permeability of the conjugate. Its non-cleavable nature ensures stability in cellular environments, making it suitable for sustained interactions with the target protein.

Ligand: The ligand component is derived from pomalidomide, a thalidomide analog known for its high affinity to the cereblon E3 ubiquitin ligase. Its structural characteristics enable the effective recruitment of the E3 ligase, promoting ubiquitination and subsequent degradation of the target protein.

Reactive Site: The hydroxyl group at the terminal of the PEG3 linker serves as the reactive site for coupling with the target protein ligand. Recommended reaction types include esterification or carbamate formation, providing versatility in conjugation strategies to attach various warheads.

Recommended Target Protein Ligand: An optimal warhead for this molecule is a small-molecule inhibitor or a peptide that can specifically bind to the protein of interest. The advantages include precise targeting and minimal off-target effects, making it ideal for applications in studying protein function and validating therapeutic targets in experimental settings.